199 related articles for article (PubMed ID: 15564137)
61. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses.
Höti N; Li Y; Chen CL; Chowdhury WH; Johns DC; Xia Q; Kabul A; Hsieh JT; Berg M; Ketner G; Lupold SE; Rodriguez R
Mol Ther; 2007 Aug; 15(8):1495-503. PubMed ID: 17565351
[TBL] [Abstract][Full Text] [Related]
62. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy.
Rancourt C; Piché A; Gomez-Navarro J; Wang M; Alvarez RD; Siegal GP; Fuller GM; Jones SA; Curiel DT
Clin Cancer Res; 1999 Jan; 5(1):43-50. PubMed ID: 9918201
[TBL] [Abstract][Full Text] [Related]
63. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters.
Rubinchik S; Lowe S; Jia Z; Norris J; Dong J
Gene Ther; 2001 Feb; 8(3):247-53. PubMed ID: 11313797
[TBL] [Abstract][Full Text] [Related]
64. Adenovirus-based therapy for prostate cancer.
Ekblad M; Halldén G
Curr Opin Mol Ther; 2010 Aug; 12(4):421-31. PubMed ID: 20677093
[TBL] [Abstract][Full Text] [Related]
65. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo.
Zhao T; Rao XM; Xie X; Li L; Thompson TC; McMasters KM; Zhou HS
Cancer Res; 2003 Jun; 63(12):3073-8. PubMed ID: 12810631
[TBL] [Abstract][Full Text] [Related]
66. [Variants of adenovirus type 5 with deletions in early genes: ability for selective replication in p53-defective human tumor cells].
Kachko AV; Sviatchenko VA; Ternovoĭ VA; Kiselev NN; Sorokin AV; Kiselev SL; Georgiev GP; Netesov SV
Mol Biol (Mosk); 2003; 37(5):868-75. PubMed ID: 14593924
[TBL] [Abstract][Full Text] [Related]
67. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy.
Okegawa T; Li Y; Pong RC; Bergelson JM; Zhou J; Hsieh JT
Cancer Res; 2000 Sep; 60(18):5031-6. PubMed ID: 11016624
[TBL] [Abstract][Full Text] [Related]
68. The development of the conditionally replication-competent adenovirus: replacement of E4 orf1-4 region by exogenous gene.
Nam JK; Lee MH; Seo HH; Kim SK; Lee KH; Kim IH; Lee SJ
J Gene Med; 2010 May; 12(5):453-62. PubMed ID: 20440756
[TBL] [Abstract][Full Text] [Related]
69. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus.
Sarkar D; Lebedeva IV; Su ZZ; Park ES; Chatman L; Vozhilla N; Dent P; Curiel DT; Fisher PB
Cancer Res; 2007 Jun; 67(11):5434-42. PubMed ID: 17545625
[TBL] [Abstract][Full Text] [Related]
70. In vivo antitumor effect of retrovirus-mediated gene transfer of the adenovirus E1a gene.
Sánchez-Prieto R; Quintanilla M; Martín P; Lleonart M; Cano A; Dotto GP; Ramón y Cajal S
Cancer Gene Ther; 1998; 5(4):215-24. PubMed ID: 9694073
[TBL] [Abstract][Full Text] [Related]
71. Adenovirus-mediated expression of a soluble fibroblast growth factor receptor inhibits in vitro growth of prostate DU145 cells.
Gowardhan B; West AF; Robson CN; Leung HY
Prostate; 2004 Sep; 61(1):50-9. PubMed ID: 15287093
[TBL] [Abstract][Full Text] [Related]
72. Technology evaluation: CV-787, Calydon Inc.
Doehn C; Jocham D
Curr Opin Mol Ther; 2001 Apr; 3(2):204-10. PubMed ID: 11338935
[TBL] [Abstract][Full Text] [Related]
73. NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen.
Lee SJ; Lee K; Yang X; Jung C; Gardner T; Kim HS; Jeng MH; Kao C
J Mol Biol; 2003 Jul; 330(4):749-60. PubMed ID: 12850144
[TBL] [Abstract][Full Text] [Related]
74. Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha.
Engler H; Machemer T; Philopena J; Wen SF; Quijano E; Ramachandra M; Tsai V; Ralston R
Virology; 2004 Oct; 328(1):52-61. PubMed ID: 15380358
[TBL] [Abstract][Full Text] [Related]
75. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter.
Ahn M; Lee SJ; Li X; Jiménez JA; Zhang YP; Bae KH; Mohammadi Y; Kao C; Gardner TA
Cancer Gene Ther; 2009 Jan; 16(1):73-82. PubMed ID: 18772902
[TBL] [Abstract][Full Text] [Related]
76. A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer.
Cheng WS; Kraaij R; Nilsson B; van der Weel L; de Ridder CM; Tötterman TH; Essand M
Mol Ther; 2004 Aug; 10(2):355-64. PubMed ID: 15294182
[TBL] [Abstract][Full Text] [Related]
77. [The specific killing of human melanoma cells by replication selective adenovirus].
Xie QJ; Lu YL; Chen ZJ; Zhang JQ; Chen HH; Ling XL; Lü P; Du ZY; Xu YJ
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):448-52. PubMed ID: 14575567
[TBL] [Abstract][Full Text] [Related]
78. Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells.
Sandberg L; Papareddy P; Silver J; Bergh A; Mei YF
Hum Gene Ther; 2009 Apr; 20(4):361-73. PubMed ID: 19199789
[TBL] [Abstract][Full Text] [Related]
79. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
[TBL] [Abstract][Full Text] [Related]
80. Prostate-Specific Membrane Antigen: Much More Than a Prostate Cancer Marker.
Chang SS; Gaudin PB; Reuter VE; O'Keefe DS; Bacich DJ; Heston WD
Mol Urol; 1999; 3(3):313-320. PubMed ID: 10851338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
